** Brokerage BofA Global Research raises PT on drugmaker AbbVie ABBV.N to $223 from $200, a 5.4% upside to the stock's last close
** Maintains "neutral" rating
** PT raise in part due to ABBV signing a licensing deal earlier this week with Danish biotech Gubra GUBRA.CO to develop an obesity treatment that mimics pancreatic hormone amylin
** Brokerage says ABBV expects weight-loss of 15% to 20% as a stand-alone product with better tolerability and less lean-muscle loss than GLP-1 drugs
** Although late-entrants into the obesity drug market could struggle to compete with incumbents Novo Nordisk NOVOb.CO and Eli Lilly LLY.N, a suite of products and/or differentiation will help, BofA says
** Stock has risen 18.2% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。